GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mizuho Medy Co Ltd (TSE:4595) » Definitions » Debt-to-EBITDA

Mizuho Medy Co (TSE:4595) Debt-to-EBITDA : 0.00 (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Mizuho Medy Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mizuho Medy Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was 円0 Mil. Mizuho Medy Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was 円0 Mil. Mizuho Medy Co's annualized EBITDA for the quarter that ended in Jun. 2024 was 円2,360 Mil. Mizuho Medy Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Mizuho Medy Co's Debt-to-EBITDA or its related term are showing as below:

During the past 10 years, the highest Debt-to-EBITDA Ratio of Mizuho Medy Co was 2.03. The lowest was 0.00. And the median was 0.97.

TSE:4595's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Debt-to-EBITDA only.

Mizuho Medy Co Debt-to-EBITDA Historical Data

The historical data trend for Mizuho Medy Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mizuho Medy Co Debt-to-EBITDA Chart

Mizuho Medy Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.51 0.97 - - -

Mizuho Medy Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mizuho Medy Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Mizuho Medy Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mizuho Medy Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mizuho Medy Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mizuho Medy Co's Debt-to-EBITDA falls into.



Mizuho Medy Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mizuho Medy Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 5347.482
=0.00

Mizuho Medy Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


Mizuho Medy Co  (TSE:4595) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Mizuho Medy Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mizuho Medy Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mizuho Medy Co Business Description

Traded in Other Exchanges
N/A
Address
4 Fujinoki-Machi, Saga Prefecture, Tosu, JPN, 841-0048
Mizuho Medy Co Ltd engages in research and development, manufacture and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.

Mizuho Medy Co Headlines

No Headlines